A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
- Conditions
- OverweightType 2 DiabetesCardiovascular DiseaseHigh Cardiovascular RiskObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14673
- Registration Number
- NCT02019264
- Locations
- 🇺🇸
InterMed, PA, Portland, Maine, United States
🇺🇸Interventional Cardiac Consultants, Trinity, Florida, United States
🇺🇸Spectrum Clinical Research, Baltimore, Maryland, United States
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT01995838
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
- Conditions
- Chronic Weight Management
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT01987427
- Locations
- 🇺🇸
Scripps Clinical Research Center, La Jolla, California, United States
🇺🇸Radiant Research - Dallas, Dallas, Texas, United States
🇺🇸National Clinical Research - Norfolk, Norfolk, Virginia, United States
Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- Drug: placebo (lower baseline platelet count)Drug: placebo (higher baseline platelet count)
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT01976104
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT01975636
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
🇺🇸Covance Laboratories, Madison, Wisconsin, United States
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- Drug: placebo (lower baseline platelet count)Drug: placebo (higher baseline platelet count)
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01972529
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
- Conditions
- KIF5B-RET-Positive Adenocarcinoma of the Lung
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01877083
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬National Cancer Center Hospital, Singapore, Singapore
🇨🇳Veterans General Hospital Taipei, Taipei, Taiwan
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
- Conditions
- Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Interventions
- Drug: E7777 9 mcg/kg
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01871727
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Yale University Cancer Center, New Haven, Connecticut, United States
An Extended Access Program for Perampanel
- Conditions
- Partial Onset Seizures
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01871233
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Australia
🇨🇿Fakultni Nemocnice U Sv. Anny V Brne, Brno, Czechia
🇦🇺Royal Melbourne Hospital, Parkville, Australia
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT01830400